GlassScriptPhysician profile
Erika Brewer
NPI 1538508726
$3,821.11
in general payments reported to CMS, 2019-2025
24 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $245 · 2021: $528 · 2022: $692 · 2023: $831 · 2024: $559 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $323.79 | 2022-2025 | Rocklatan, Hydrus Microstent, Tryptyr |
| Bausch & Lomb Americas INC. | $292.74 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $284.72 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $280.81 | 2019-2025 | Tecnis Iol, Tecnis Iol, Veritas Vision System |
| Aerie Pharmaceuticals, INC. | $275.77 | 2020-2021 | |
| Amgen INC. | $257.89 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $251.93 | 2019-2025 | |
| New World Medical,INC. | $183.50 | 2022-2023 | |
| Thea Pharma INC. | $175.96 | 2022-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $175.68 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $166.95 | 2019-2021 | |
| Ivantis, INC | $163.12 | 2020 | |
| Apellis Pharmaceuticals, INC. | $150.97 | 2023 | Syfovre |
| Allergan, INC. | $140.80 | 2021-2022 | |
| Horizon Therapeutics Plc | $130.85 | 2022-2023 | Tepezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $112.48 | 2022-2024 | Alphagan P, Lumigan, Xen Glaucoma Treatment System |
| Genentech USA, INC. | $111.15 | 2024-2025 | Vabysmo |
| Harrow Eye, LLC | $94.54 | 2024-2025 | Vevye |
| Akorn Operating Company LLC | $62.18 | 2021 | |
| Glaukos Corporation | $53.90 | 2025 | Istent Infinite |
| Biotissue Holdings INC. | $46.67 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $36.34 | 2023 | Contact Lens, Spectacle Lenses |
| Dompe US, INC. | $26.06 | 2022 | |
| Sight Sciences, INC. | $22.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.